Recurrent Primary Sclerosing Cholangitis: Current Understanding, Management, and Future Directions

Kristel K. Leung; Maya Deeb; Sandra E. Fischer; Aliya Gulamhusein

doi:10.1055/s-0041-1730950

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2021; 41(03): 409-420
DOI: 10.1055/s-0041-1730950

Review Article

Recurrent Primary Sclerosing Cholangitis: Current Understanding, Management, and Future Directions

Authors

Kristel K. Leung

¹Division of Gastroenterology and Hepatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Maya Deeb

¹Division of Gastroenterology and Hepatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
Sandra E. Fischer

²Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada
Aliya Gulamhusein

¹Division of Gastroenterology and Hepatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

³Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada

Abstract

Patients with primary sclerosing cholangitis (PSC) constitute 5 to 15% of patients listed for liver transplantation worldwide. Although post-transplant outcomes are favorable, recurrent PSC (rPSC) occurs in an important subset of patients, with higher prevalence rates reported with increasing time from transplant. Given its association with poor graft outcomes and risk of retransplant, effort has been made to understand rPSC, its pathophysiology, and risk factors. This review covers these facets of rPSC and focuses on implicated risk factors including pretransplant recipient characteristics, inflammatory bowel-disease-related factors, and donor-specific and transplant-specific factors. Confirming a diagnosis of rPSC requires thoughtful consideration of alternative etiologies so as to ensure confidence in diagnosis, management, subsequent risk assessment, and counseling for patients. Unfortunately, no cure exists for rPSC; however, future large-scale efforts are underway to better characterize the natural history of rPSC and its associated risk factors with hopes of identifying potential key targets for novel therapies.

Keywords

recurrent primary sclerosing cholangitis - posttransplant complications - inflammatory bowel disease

Volltext

Referenzen

References
1 Chapman RW, Arborgh BA, Rhodes JM. et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21 (10) 870-877
2 Chapman MH, Thorburn D, Hirschfield GM. et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut 2019; 68 (08) 1356-1378
3 Jepsen P, Grønbæk L, Vilstrup H. Worldwide incidence of autoimmune liver disease. Dig Dis 2015; 33 (Suppl. 02) 2-12
4 Molodecky NA, Kareemi H, Parab R. et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 2011; 53 (05) 1590-1599
5 Dyson JK, Blain A, Foster Shirley MD, Hudson M, Rushton S, Jeffreys Jones DE. Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis. JHEP Rep 2020; 3 (01) 100202
6 Boonstra K, Weersma RK, van Erpecum KJ. et al; EpiPSCPBC Study Group. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013; 58 (06) 2045-2055
7 Lunder AK, Hov JR, Borthne A. et al. Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease. Gastroenterology 2016; 151 (04) 660.e4-669.e4
8 Silveira M-G, Lindor K-D. Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol 2008; 14 (21) 3338-3349
9 Björnsson E. Small-duct primary sclerosing cholangitis. Curr Gastroenterol Rep 2009; 11 (01) 37-41
10 Björnsson E, Olsson R, Bergquist A. et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008; 134 (04) 975-980
11 Björnsson E, Boberg KM, Cullen S. et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 2002; 51 (05) 731-735
12 Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002; 35 (06) 1494-1500
13 Tanaka A. IgG4-related sclerosing cholangitis and primary sclerosing cholangitis. Gut Liver 2019; 13 (03) 300-307
14 Hennes EM, Zeniya M, Czaja AJ. et al; International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48 (01) 169-176
15 Kerkar N, Chan A. Autoimmune hepatitis, sclerosing cholangitis, and autoimmune sclerosing cholangitis or overlap syndrome. Clin Liver Dis 2018; 22 (04) 689-702
16 Freedman BL, Danford CJ, Patwardhan V, Bonder A. Treatment of overlap syndromes in autoimmune liver disease: a systematic review and meta-analysis. J Clin Med 2020; 9 (05) 1449
17 Kamisawa T, Nakazawa T, Tazuma S. et al. Clinical practice guidelines for IgG4-related sclerosing cholangitis. J Hepatobiliary Pancreat Sci 2019; 26 (01) 9-42
18 Loftus Jr EV, Sandborn WJ, Lindor KD, Larusso NF. Interactions between chronic liver disease and inflammatory bowel disease. Inflamm Bowel Dis 1997; 3 (04) 288-302
19 de Vries AB, Janse M, Blokzijl H, Weersma RK. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol 2015; 21 (06) 1956-1971
20 Shiau H, Ihekweazu FD, Amin M, Fofanova T, Miloh T, Kellermayer R. Unique inflammatory bowel disease phenotype of pediatric primary sclerosing cholangitis: a single-center study. J Pediatr Gastroenterol Nutr 2017; 65 (04) 404-409
21 Loftus Jr EV, Harewood GC, Loftus CG. et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54 (01) 91-96
22 Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50 (01) 158-164
23 Gulamhusein AF, Eaton JE, Tabibian JH, Atkinson EJ, Juran BD, Lazaridis KN. Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD. Am J Gastroenterol 2016; 111 (05) 705-711
24 Trivedi PJ, Crothers H, Mytton J. et al. Effects of primary sclerosing cholangitis on risks of cancer and death in people with inflammatory bowel disease, based on sex, race, and age. Gastroenterology 2020; 159 (03) 915-928
25 Weismüller TJ, Trivedi PJ, Bergquist A. et al; International PSC Study Group. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 2017; 152 (08) 1975.e8-1984.e8
26 Lindor KD, Kowdley KV, Harrison ME. American College of Gastroenterology. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol 2015; 110 (05) 646-659 , quiz 660
27 Lindor KD. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. Ursodiol for primary sclerosing cholangitis. N Engl J Med 1997; 336 (10) 691-695
28 Eaton JE, Silveira MG, Pardi DS. et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011; 106 (09) 1638-1645
29 Singh S, Khanna S, Pardi DS, Loftus Jr EV, Talwalkar JA. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2013; 19 (08) 1631-1638
30 Lindor KD, Kowdley KV, Luketic VAC. et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50 (03) 808-814
31 Rupp C, Hippchen T, Bruckner T. et al. Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis. Gut 2019; 68 (12) 2170-2178
32 Martin EF, Levy C. Timing, management, and outcomes of liver transplantation in primary sclerosing cholangitis. Semin Liver Dis 2017; 37 (04) 305-313
33 Darwish Murad S, Kim WR, Harnois DM. et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143 (01) 88-98.e3 , quiz e14
34 Mantel HT, Westerkamp AC, Adam R. et al; European Liver and Intestine Transplant Association (ELITA). Strict selection alone of patients undergoing liver transplantation for hilar cholangiocarcinoma is associated with improved survival. PLoS One 2016; 11 (06) e0156127
35 Sapisochin G, Facciuto M, Rubbia-Brandt L. et al; iCCA International Consortium. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment. Hepatology 2016; 64 (04) 1178-1188
36 Vallin M, Sturm N, Lamblin G. et al. Unrecognized intrahepatic cholangiocarcinoma: an analysis of 993 adult cirrhotic liver explants. Clin Transplant 2013; 27 (03) 403-409
37 Fosby B, Melum E, Bjøro K. et al. Liver transplantation in the Nordic countries - an intention to treat and post-transplant analysis from The Nordic Liver Transplant Registry 1982-2013. Scand J Gastroenterol 2015; 50 (06) 797-808
38 Klose J, Klose MA, Metz C. et al. Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the model for end-stage liver disease era. Langenbecks Arch Surg 2014; 399 (08) 1021-1029
39 Goldberg D, French B, Thomasson A, Reddy KR, Halpern SD. Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era. Liver Transpl 2011; 17 (11) 1355-1363
40 Goldberg DS, French B, Thomasson A, Reddy KR, Halpern SD. Current trends in living donor liver transplantation for primary sclerosing cholangitis. Transplantation 2011; 91 (10) 1148-1152
41 Gordon FD, Goldberg DS, Goodrich NP. et al. Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: comparison of risk factors between living and deceased donor recipients. Liver Transpl 2016; 22 (09) 1214-1222
42 Sheng R, Campbell WL, Zajko AB, Baron RL. Cholangiographic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: evidence of recurrent disease. AJR Am J Roentgenol 1996; 166 (05) 1109-1113
43 Harrison RF, Davies MH, Neuberger JM, Hubscher SG. Fibrous and obliterative cholangitis in liver allografts: evidence of recurrent primary sclerosing cholangitis?. Hepatology 1994; 20 (02) 356-361
44 Graziadei IW, Wiesner RH, Batts KP. et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999; 29 (04) 1050-1056
45 Abt P, Crawford M, Desai N, Markmann J, Olthoff K, Shaked A. Liver transplantation from controlled non-heart-beating donors: an increased incidence of biliary complications. Transplantation 2003; 75 (10) 1659-1663
46 Song GW, Lee SG, Hwang S. et al. Biliary stricture is the only concern in ABO-incompatible adult living donor liver transplantation in the rituximab era. J Hepatol 2014; 61 (03) 575-582
47 Lee M. Antibody-mediated rejection after liver transplant. Gastroenterol Clin North Am 2017; 46 (02) 297-309
48 Rauber C, Bartelheimer K, Zhou T. et al. Prevalence of human herpesviruses in biliary fluid and their association with biliary complications after liver transplantation. BMC Gastroenterol 2019; 19 (01) 110
49 Verdonk RC, Buis CI, van der Jagt EJ. et al. Nonanastomotic biliary strictures after liver transplantation, part 2: management, outcome, and risk factors for disease progression. Liver Transpl 2007; 13 (05) 725-732
50 Lim JH, Mairiang E, Ahn GH. Biliary parasitic diseases including clonorchiasis, opisthorchiasis and fascioliasis. Abdom Imaging 2008; 33 (02) 157-165
51 Gordon F. Recurrent primary sclerosing cholangitis: clinical diagnosis and long-term management issues. Liver Transpl 2006; 12 (11, Suppl 2): S73-S75
52 McPartland KJ, Lewis WD, Gordon FD. et al. Post-liver transplant cholestatic disorder with biliary strictures: de novo versus recurrent primary sclerosing cholangitis. Pathol Int 2009; 59 (05) 312-316
53 Kashyap R, Mantry P, Sharma R. et al. Comparative analysis of outcomes in living and deceased donor liver transplants for primary sclerosing cholangitis. J Gastrointest Surg 2009; 13 (08) 1480-1486
54 Trivedi PJ, Scalera I, Slaney E. et al. Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis. J Hepatol 2017; 67 (05) 957-965
55 Egawa H, Ueda Y, Ichida T. et al. Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation in Japanese registry. Am J Transplant 2011; 11 (03) 518-527
56 Soufi N, Bazerbachi F, Deneau M. Post-transplant disease recurrence in pediatric PSC. Curr Gastroenterol Rep 2018; 20 (09) 44
57 Pollheimer MJ, Halilbasic E, Fickert P, Trauner M. Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2011; 25 (06) 727-739
58 Noguchi K, Kobayashi M, Yagihashi A. et al. HLA antigens in primary sclerosing cholangitis. Transplant Proc 1992; 24 (06) 2775-2776
59 Farh KK-H, Marson A, Zhu J. et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 2015; 518 (7539): 337-343
60 Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013; 145 (03) 521-536
61 Shah A, Macdonald GA, Morrison M, Holtmann G. Targeting the gut microbiome as a treatment for primary sclerosing cholangitis: a conceptional framework. Am J Gastroenterol 2020; 115 (06) 814-822
62 Kummen M, Thingholm LB, Rühlemann MC. et al. Altered gut microbial metabolism of essential nutrients in primary sclerosing cholangitis. Gastroenterology 2021; 160 (05) P1784-P1798
63 Jeyarajah DR, Netto GJ, Lee SP. et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process?. Transplantation 1998; 66 (10) 1300-1306
64 Miki C, Harrison JD, Gunson BK, Buckels JA, McMaster P, Mayer AD. Inflammatory bowel disease in primary sclerosing cholangitis: an analysis of patients undergoing liver transplantation. Br J Surg 1995; 82 (08) 1114-1117
65 Abu-Elmagd K, Demetris J, Rakela J. et al. Recurrence of primary sclerosing cholangitis (PSC) after hepatic transplantation: single center experience with 380 grafts. Transplantation 1999; 67: S236
66 Alabraba E, Nightingale P, Gunson B. et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009; 15 (03) 330-340
67 Moncrief KJ, Savu A, Ma MM, Bain VG, Wong WW, Tandon P. The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation--a single-centre experience. Can J Gastroenterol 2010; 24 (01) 40-46
68 Vera A, Moledina S, Gunson B. et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002; 360 (9349): 1943-1944
69 Steenstraten IC, Sebib Korkmaz K, Trivedi PJ. et al. Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation. Aliment Pharmacol Ther 2019; 49 (06) 636-643
70 Hildebrand T, Pannicke N, Dechene A. et al; German PSC Study Group. Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: a retrospective multicenter analysis. Liver Transpl 2016; 22 (01) 42-52
71 Zhang L, Lewis JT, Abraham SC. et al. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am J Surg Pathol 2010; 34 (01) 88-94
72 Trivedi PJ, Adams DH. Gut-liver immunity. J Hepatol 2016; 64 (05) 1187-1189
73 Dawson PA. Toxic bile and sclerosing cholangitis: Is there a role for pharmacological interruption of the bile acid enterohepatic circulation?. Hepatology 2016; 63 (02) 363-364
74 Miloh T, Anand R, Yin W, Vos M, Kerkar N, Alonso E. Studies of Pediatric Liver Transplantation Research Group. Pediatric liver transplantation for primary sclerosing cholangitis. Liver Transpl 2011; 17 (08) 925-933
75 Cholongitas E, Shusang V, Papatheodoridis GV. et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008; 14 (02) 138-143
76 Kugelmas M, Spiegelman P, Osgood MJ. et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2003; 9 (07) 727-732
77 Ravikumar R, Tsochatzis E, Jose S. et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol 2015; 63 (05) 1139-1146
78 Lindström L, Jørgensen KK, Boberg KM. et al. Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic multicentre study. Scand J Gastroenterol 2018; 53 (03) 297-304
79 Buchholz BM, Lykoudis PM, Ravikumar R, Pollok JM, Fusai GK. Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients. World J Gastroenterol 2018; 24 (28) 3171-3180
80 Trivedi PJ, Reece J, Laing RW. et al. The impact of ileal pouch-anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis. Aliment Pharmacol Ther 2018; 48 (03) 322-332
81 Alexander J, Lord JD, Yeh MM, Cuevas C, Bakthavatsalam R, Kowdley KV. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008; 14 (02) 245-251
82 Ueda Y, Kaido T, Okajima H. et al. Long-term prognosis and recurrence of primary sclerosing cholangitis after liver transplantation: a single-center experience. Transplant Direct 2017; 3 (12) e334-e334
83 Takaya S, Jain A, Yagihashi A. et al. Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Transplant Proc 1999; 31 (05) 2028-2031
84 Batts KP, Moore SB, Perkins JD, Wiesner RH, Grambsch PM, Krom RA. Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts. Transplantation 1988; 45 (02) 376-379
85 den Dulk AC, Shi X, Verhoeven CJ. et al. Donor-specific anti-HLA antibodies are not associated with nonanastomotic biliary strictures but both are independent risk factors for graft loss after liver transplantation. Clin Transplant 2018; 32 (02) e13163
86 Yamada Y, Hoshino K, Fuchimoto Y. et al. Rituximab induction to prevent the recurrence of PSC after liver transplantation-the lessons learned from ABO-incompatible living donor liver transplantation. Transplant Direct 2018; 4 (02) e342-e342
87 Thurairajah PH, Carbone M, Bridgestock H. et al. Late acute liver allograft rejection; a study of its natural history and graft survival in the current era. Transplantation 2013; 95 (07) 955-959
88 Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25 (03) 658-663
89 Brandsaeter B, Schrumpf E, Bentdal O. et al. Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl 2005; 11 (11) 1361-1369
90 Aydogan C, Sevmis S, Aktas S, Karakayali H, Demirhan B, Haberal M. Steroid-resistant acute rejections after liver transplant. Exp Clin Transplant 2010; 8 (02) 172-177
91 Venkat VL, Ranganathan S, Mazariegos GV, Sun Q, Sindhi R. Recurrence of primary sclerosing cholangitis in pediatric liver transplant recipients. Liver Transpl 2014; 20 (06) 679-686
92 Talukdar A, AshokKumar C, Farrar J. et al. Lymphocyte subset reconstitution in pediatric liver recipients induced with steroid-free rabbit anti-human thymocyte globulin. Pediatr Transplant 2008; 12 (07) 804-808
93 Tamura S, Sugawara Y, Kaneko J, Matsui Y, Togashi J, Makuuchi M. Recurrence of primary sclerosing cholangitis after living donor liver transplantation. Liver Int 2007; 27 (01) 86-94
94 Campsen J, Zimmerman MA, Trotter JF. et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl 2008; 14 (02) 181-185
95 Khettry U, Keaveny A, Goldar-Najafi A. et al. Liver transplantation for primary sclerosing cholangitis: a long-term clinicopathologic study. Hum Pathol 2003; 34 (11) 1127-1136
96 Sutton ME, Bense RD, Lisman T, van der Jagt EJ, van den Berg AP, Porte RJ. Duct-to-duct reconstruction in liver transplantation for primary sclerosing cholangitis is associated with fewer biliary complications in comparison with hepaticojejunostomy. Liver Transpl 2014; 20 (04) 457-463
97 Pandanaboyana S, Bell R, Bartlett AJ, McCall J, Hidalgo E. Meta-analysis of Duct-to-duct versus Roux-en-Y biliary reconstruction following liver transplantation for primary sclerosing cholangitis. Transpl Int 2015; 28 (04) 485-491
98 Mantel HT, Rosen CB, Heimbach JK. et al. Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl 2007; 13 (10) 1372-1381
99 Fosby B, Karlsen TH, Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 2012; 18 (01) 1-15
100 Lee HW, Shah NH, Lee SK. An update on endoscopic management of post-liver transplant biliary complications. Clin Endosc 2017; 50 (05) 451-463
101 Moy BT, Birk JW. A review on the management of biliary complications after orthotopic liver transplantation. J Clin Transl Hepatol 2019; 7 (01) 61-71
102 Corpechot C, Chazouillères O, Belnou P. et al; Global PBC Study Group. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. J Hepatol 2020; 73 (03) 559-565
103 Hey P, Lokan J, Johnson P. et al. Efficacy of oral vancomycin in recurrent primary sclerosing cholangitis following liver transplantation. BMJ Case Rep 2017; 2017: bcr2017221165
104 Buness C, Lindor KD, Miloh T. Oral vancomycin therapy in a child with primary sclerosing cholangitis and severe ulcerative colitis. Pediatr Gastroenterol Hepatol Nutr 2016; 19 (03) 210-213
105 Rahimpour S, Nasiri-Toosi M, Khalili H, Ebrahimi-Daryani N, Nouri-Taromlou MK, Azizi Z. A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study. J Gastrointestin Liver Dis 2016; 25 (04) 457-464
106 Tabibian JH, Weeding E, Jorgensen RA. et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther 2013; 37 (06) 604-612
107 Mouchli MA, Singh S, Loftus Jr EVJ. et al. Risk factors and outcomes of de novo cancers (excluding nonmelanoma skin cancer) after liver transplantation for primary sclerosing cholangitis. Transplantation 2017; 101 (08) 1859-1866
108 Vera A, Gunson BK, Ussatoff V. et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 2003; 75 (12) 1983-1988
109 Peverelle M, Paleri S, Hughes J, De Cruz P, Gow PJ. Activity of inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis predicts poorer clinical outcomes. Inflamm Bowel Dis 2020; 26 (12) 1901-1908
110 Joshi D, Bjarnason I, Belgaumkar A. et al. The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis. Liver Int 2013; 33 (01) 53-61
111 Mouchli MA, Singh S, Boardman L. et al. Natural history of established and de novo inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Inflamm Bowel Dis 2018; 24 (05) 1074-1081